abstract |
Metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer after treatment with abiraterone acetate in human male patients A method of treating cancer or high-risk localized prostate cancer. For use in combination with (a) abiraterone acetate and (b) prednisolone in a method of treatment comprising administering a dose of about 30 mg / day to about 480 mg / day of a compound of formula (I): Pharmaceutical composition. [Selection figure] None |